• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya Therapeutics Cetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact
Cetya Therapeutics announces STTR grant

Cetya Therapeutics announces STTR grant

Sep 22, 2017 | Posted by Cetya Therapeutics |

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

Share

Recent Posts

  • Cetya Therapeutics Appoints Ron Lowy to Board of Directors
  • Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
  • Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors
  • Cetya Therapeutics Announces Phase II STTR Grant Award
  • Cetya Therapeutics announces advanced industries award

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com
Cetya Therapeutics, Inc.

2401 Research Boulevard, Suite 204
Fort Collins, CO 80526

© 2018 · Cetya Therapeutics

Prev Next